Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
Bayer (Finland)
h-index: 22
Total citations: 2,124
Total papers: 84
Homepage:
http://www.bayer.fi/
Recent papers from Bayer (Finland)
Acute Perinatal Stroke Characteristics and Outcome in Southern Finland
Acta Paediatrica · 2026
Executive Selection Has a Criterion Problem: A Perspective on Capability‐Centered Assessment Under Strategic Uncertainty
International Journal of Selection and Assessment · 2026
Low Analytical Evaluation Threshold in Leachables Screening: Challenges, Potential Solutions and Alternative Approaches
Pharmaceutical Research · 2026
Consistency of efficacy and safety of elinzanetant for vasomotor symptoms and sleep disturbance associated with menopause across different populations: a review of the OASIS clinical trial program
Maturitas · 2026
Multifactorial Nature of Childhood Stroke Presents a Major Challenge for Diagnosis and Management: A Population‐Based Study From Southern Finland
Acta Paediatrica · 2026
Finerenone in Persons with Chronic Kidney Disease without Diabetes
New England Journal of Medicine · 2026
Effect of elinzanetant on sleep disturbance and aspects of quality of life in women with breast cancer experiencing vasomotor symptoms: OASIS-4 subgroup analysis by type of endocrine therapy.
Journal of Clinical Oncology · 2026
604P Pharmacokinetics, compliance and estradiol levels in women with breast cancer receiving elinzanetant for the treatment of endocrine therapy-associated vasomotor symptoms
ESMO Open · 2026
Efficacy and Safety of Vilaprisan in the Treatment of Uterine Fibroids: Data from ASTEROID 5, a Phase 3 Multicenter Randomized Controlled Trial
Journal of Clinical Medicine · 2026
Levonorgestrel-releasing intrauterine system treatment for endometrial hyperplasia and early endometrial cancer: a systematic review
Therapeutic Advances in Reproductive Health · 2026
Operationalizing Decentralized Clinical Trials: Technology Insights from the Trials@Home RADIAL Proof‐of‐Concept Trial
Clinical Pharmacology & Therapeutics · 2025
Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause
JAMA Internal Medicine · 2025
Bringing Trial Activities to Participants—The Trials@Home RADIAL Proof‐of‐Concept Trial Investigating Decentralization of Trials
Clinical Pharmacology & Therapeutics · 2025
Exit Interviews Examining Changes to Mood and Work/Productivity Impacts Related to Vasomotor Symptoms: Perspectives of Postmenopausal Women Receiving Elinzanetant in Phase III Clinical Trials
Patient · 2025
Realizing the benefits of the estimand framework when reporting and communicating clinical trial results—some recommendations
Trials · 2025
Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer
New England Journal of Medicine · 2025
Effects of LinTT1-peptide conjugation on the properties of poly(ethylene glycol)-block-(ε-caprolactone) nanoparticles prepared by the nanoprecipitation method
Drug Delivery and Translational Research · 2025
Worsening Heart Failure and Medication Use in HFrEF: A Finnish Retrospective Registry Study and Patient Survey
International Journal of Heart Failure · 2025
Toward understanding lipid reorganization in RNA lipid nanoparticles in acidic environments
Proceedings of the National Academy of Sciences · 2024
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial
Nephrology Dialysis Transplantation · 2024